HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma.

Abstract
While most resection specimens from patients with neoadjuvantly treated esophageal squamous cell carcinoma show therapy-related changes in the form of inflammation and fibrosis, others harbor a florid foreign body-type giant cell response to keratin debris. The purpose of our study was to perform a detailed clinicopathologic analysis of these histologic types of treatment responses and correlate these findings with patient outcome. Clinical and pathologic parameters from 110 esophagogastrectomies were recorded and analyzed. Two main types of histologic responses were observed: inflammatory-predominant response (59%) and florid foreign body-type giant cell response to keratin (41%). Irrespective of cG, cTNM, and amount of residual cancer, florid foreign body-type giant cell reaction was predominantly noted deep within the esophageal wall, while the inflammatory response was restricted to the mucosa, submucosa, and inner half of muscularis propria. Patients with foreign body-type giant cell response showed significantly better overall survival compared with the inflammatory response group (log-rank test P=0.015). Florid foreign body-type giant cell response was the only factor associated with improved survival in a multivariable analysis for overall survival (hazard ratio=0.5; 95% confidence interval=0.3-1.0; P=0.038), but not in the model for disease-specific survival, whereas ypTNM stage II was the only significant risk factor for disease-specific survival in multivariable analysis (hazard ratio=3.4; 95% confidence interval=1.0-11.2; P=0.047). Our results suggest that in addition to the College of American Pathologists Tumor Regression Score and ypTNM stage, subtype of histologic response to therapy may represent another prognostic marker for neoadjuvantly treated esophageal squamous cell carcinoma.
AuthorsWei Chen, Lei Zhao, Agoston Agoston, Abby White, Emanuele Mazzola, Patrick J Boyle, Vikram Deshpande, Jason L Hornick, Raphael Bueno, Adam J Bass, Peter Enzinger, Harvey Mamon, Mark Redston, Deepa T Patil
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 45 Issue 12 Pg. 1648-1660 (12 01 2021) ISSN: 1532-0979 [Electronic] United States
PMID34469333 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Keratins
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (analysis)
  • Chemotherapy, Adjuvant
  • Esophageal Neoplasms (chemistry, mortality, pathology, therapy)
  • Esophageal Squamous Cell Carcinoma (mortality, pathology, therapy)
  • Esophagectomy (adverse effects, mortality)
  • Female
  • Gastrectomy (adverse effects, mortality)
  • Granuloma, Foreign-Body (pathology)
  • Humans
  • Keratins (analysis)
  • Male
  • Middle Aged
  • Neoadjuvant Therapy (adverse effects, mortality)
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: